Tuberculosis Treatment Market Size, Share Analysis and Forecast Report (2026-2035)

Tuberculosis Treatment Market: Introduction and Insights

Tuberculosis (TB) is an infectious disease that primarily affects the lungs. Tuberculosis bacteria spread from person to person via tiny droplets released into the air by coughs and sneezes, it can also attack other organs, such as the kidneys, spine, and brain. Not everyone who is infected with tuberculosis bacteria (germs) becomes ill. There are two kinds of tuberculosis:

• Latent tuberculosis infection, in which the TB germs live in the body but do not lead to illness.

• Tuberculosis disease (active TB), in which the patient becomes ill as a result of the TB germs. Antibiotics can almost always cure tuberculosis, however, if not treated properly, it can be fatal.

The prevalence of tuberculosis is rapidly rising and is likely to continue rising in the coming years as well, driven by the rising number of smokers. Majority of people who have TB germs in their bodies do not develop TB disease, instead, they have latent tuberculosis infection. Tuberculosis can spread when a person with active TB disease sneezes, coughs, sings, talks, or even laughs, anything that involves releasing germs into the air. While latent TB does not get transmitted, active pulmonary infection is highly contagious.

Inactive tuberculosis does not cause symptoms; however, they can be diagnosed with a positive skin reaction test or blood test. Active TB patients may exhibit any of the following symptoms:

• Coughing Fits

• Chest Pain

• Blood or Sputum Coughing (Mucus)

• Weakness Or Fatigue

• Appetite Loss

• Loss Of Weight

• Chills

• Fever

• Sweating

There are two types of tuberculosis screening tests, namely Mantoux Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (blood test) (IGRA).

A healthcare provider will inject a small amount of purified protein derivative (PPD) under the skin of the forearm for the TST.

Additional tests to determine whether an infection is active or whether the lungs are infected include sputum and lung fluid testing, X-ray of the chest, and/or CT scans (computed tomography).

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

Global Tuberculosis Treatment Market: Epidemiology

More than 1.7 billion people (roughly 22% of the world's population) are estimated to be infected with tuberculosis. The global incidence of tuberculosis peaked around 2003 and appears to be slowly declining. According to the World Health Organization (WHO), 9.9 million people became ill with tuberculosis (TB) in 2020, with 1.5 million deaths.

As per the records, in 2021, there was 7,860 tuberculosis cases reported in the United States. The incidence rate in the United States has reached close to 2.4 cases per 100,000 people.

Global Tuberculosis Treatment Market- Therapeutic Landscape

Antibiotics are typically used to treat tuberculosis (TB) in the initial treatment, which goes on for several months. The standard treatment is 6 months of antibiotics (isoniazid and rifampicin). For the first 2 months of the 6-month treatment period, 2 additional antibiotics (pyrazinamide and ethambutol) are administered. Extrapulmonary tuberculosis (TB that occurs outside the lungs) can be treated with the same antibiotic combination as pulmonary tuberculosis.

If tuberculosis is in areas such as the brain or the sac surrounding the heart (pericardium), the patient may be given a corticosteroid such as prednisolone, alongside the antibiotics for several weeks. This will aid in the reduction of swelling in the affected areas.

If latent tuberculosis is thought to be drug-resistant, it is not always treated. If this is the case, the patient may be monitored on a regular basis to ensure that the infection does not become active. For latent tuberculosis patients, the most common prescription includes Rifampicin and isoniazid in combination for 3 months, and Isoniazid alone for 6 months.

Global Tuberculosis Treatment Market Scenario

The increased public-private partnership, favourable government policies to boost the demand for tuberculosis (TB) diagnostics, and the rising incidence of tuberculosis in high-burden countries are the factors driving the global tuberculosis treatment market.

In the forecast year, the limitations of existing tuberculosis diagnostics will impede the market growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global tuberculosis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Johnson And Johnson Services, Inc.
• Lupin Ltd
• Novartis AG
• Macleods Pharmaceuticals Ltd.
• Otsuka Pharmaceutical Co., Ltd
• Pfizer Inc.
• AstraZeneca Plc
• Cipla Ltd
• Alkem Laboratories Ltd
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• Viatris Inc. (Mylan N.V.)
• Teva Pharmaceutical Industries, Ltd.

Our Top Selling Reports

eHealth Market

Ascites Market

Heparin Market

United States Lancets Market

Erythema Market

Cryostat Market

Eye Care Market

Hospital Market

Dialysis Market

Tele-ICU Market

Tuberculosis Treatment Market Report Snapshots

Tuberculosis Treatment Companies